SystImmune Receives FDA Clearance of IND Application for Bispecific Antibody SI-B037

approvedSI-B037Positive

AI Analysis

Summary

SystImmune received FDA clearance for its IND application for SI-B037, a bispecific antibody, marking the company's first IND enabled by pioneering New Approach Methodologies.

Outcome Details

FDA cleared IND application for bispecific antibody SI-B037

Importance:6/10

Sentiment:

0.70

IND clearancebispecific antibodyFDANew Approach MethodologiesNAMs

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Clinical Trials on September 22, 2026 11:00 AM

Read Original